No evidence of a role for PPARγ Pro12Ala polymorphism in endometrial cancer susceptibility

Pharmacogenetics

Volumn 14, Issue 12, 2004, Pages 851-856

  Paynter, Randi A ^a,d   Hankinson, Susan E ^a,c   Colditz, Graham A ^a,b,c   Hunter, David J ^a,b,c   De Vivo, Immaculata ^a,b,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD CENTER FOR CANCER PREVENTION   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endometrial cancer; Haplotype; Polymorphism; PPAR

Indexed keywords

ALANINE; ANDROGEN; ANDROSTENEDIONE; AROMATASE; ESTRADIOL; ESTROGEN; ESTRONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; TESTOSTERONE;

ADIPOSE TISSUE; ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CODON; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; AMINO ACID SUBSTITUTION; BLOOD; CARCINOMA; CASE CONTROL STUDY; CAUCASIAN; DISEASE PREDISPOSITION; ENDOMETRIUM TUMOR; GENETICS; METABOLISM; MIDDLE AGED; NURSE; RISK FACTOR; STATISTICS;

ALANINE; ALLELES; AMINO ACID SUBSTITUTION; ANDROSTENEDIONE; AROMATASE; CARCINOMA; CASE-CONTROL STUDIES; CODON; DISEASE SUSCEPTIBILITY; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTRONE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HAPLOTYPES; HUMANS; MIDDLE AGED; NURSES; POLYMORPHISM, GENETIC; PPAR GAMMA; RISK FACTORS; TESTOSTERONE;

EID: 11144224617     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200412000-00008     Document Type: Article

References (31)

1. Gurnell M. PPARgamma and metabolism: insights from the study of human genetic variants. Clin Endocrinol (Oxf) 2003; 59:267-277.
2. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genet 1998; 20:284-287.
3. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genet 2000; 26:76-80.
4. Memisoglu A, Hu FB, Hankinson SE, Liu S, Meigs JB, Altshuler DM, et al. Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARgamma gene and type 2 diabetes. Diabetes Care 2003; 26:2915-2917.
5. Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 2000; 16:145-171.
6. Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993; 77:1622-1628.
7. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, et al. Aromatase - a brief overview. Annu Rev Physiol 2002; 64:93-127.
8. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000; 60:1604-1608.
9. Mu YM, Yanase T, Nishi Y, Waseda N, Oda T, Tanaka A, et al. Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun 2000; 271:710-713.
10. Mu YM, Yanase T, Nishi Y, Takayanagi R, Goto K, Nawata H. Combined treatment with specific ligands for PPARgamma: RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells. Mol Cell Endocrinol 2001; 181:239-248.
11. Yanase T, Mu YM, Nishi Y, Goto K, Nomura M, Okabe T, et al. Regulation of aromatase by nuclear receptors. J Steroid Biochem Mol Biol 2001; 79:187-192.
12. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomark Prev 1995; 4:649-654.
13. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998; 90:1292-1299.
14. Liang KY, Zeger SL. Regression analysis for correlated data. Annu Rev Public Health 1993; 14:43-68.
15. Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 2002; 53:79-91.
16. Memisoglu A, Hankinson SE, Manson JE, Colditz GA, Hunter DJ. Lack of association of the codon 12 polymorphism of the peroxisome proliferator- activated receptor gamma gene with breast cancer and body mass. Pharmacogenetics 2002; 12:597-603.
17. Berstein LM, Imyanitov EN, Suspitsin EN, Grigoriev MY, Sokolov EP, Togo A, et al. CYP19 gene polymorphism in endometrial cancer patients. J Cancer Res Clin Oncol 2001; 127:135-138.
18. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann NY Acad Sci 2001; 943:296-315.
19. Simpson ER. Aromatization of androgens in women: current concepts and findings. Fertil Steril 2002; 77 (suppl 4):S6-S10.
20. Rubin GL, Duong JH, Clyne CD, Speed CJ, Murata Y, Gong C, et al. Ligands for the peroxisomal proliferator-activated receptor gamma and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose. Endocrinology 2002; 143:2863-2871.
21. Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 1999; 79:456-463.
22. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Borresen-Dale AL. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998; 8:43-48.
23. Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999; 6:165-173.
24. Healey CS, Dunning AM, Durocher F, Teare D, Pharoah PD, Luben RN, et al. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 2000; 21:189-193.
25. Haiman CA, Hankinson SE, Spiegelman D, De Vivo I, Colditz GA, Willett WC, et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000; 87:204-210.
26. Baxter SW, Choong DY, Eccles DM, Campbell IG. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001; 22:347-349.
27. Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, et al. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000; 19:1329-1333.
28. Haiman CA, Hankinson SE, Spiegelman D, Brown M, Hunter DJ. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomark Prev 2002; 11:215-216.
29. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004; 96:936-945.
30. Garcia-Closas M, Lubin JH. Power and sample size calculations in case-control studies of gene-environment interactions: comments on different approaches. Am J Epidemiol 1999; 149:689-692.
31. Levin ML. The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum 1953; 9:531-541.